Cite
Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
MLA
Reiner, Anne S., et al. “Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.” Journal of the National Cancer Institute, vol. 112, no. 12, Dec. 2020, pp. 1275–79. EBSCOhost, https://doi.org/10.1093/jnci/djaa031.
APA
Reiner, A. S., Robson, M. E., Mellemkjær, L., Tischkowitz, M., John, E. M., Lynch, C. F., Brooks, J. D., Boice, J. D., Knight, J. A., Teraoka, S. N., Liang, X., Woods, M., Shen, R., Shore, R. E., Stram, D. O., Thomas, D. C., Malone, K. E., Bernstein, L., Riaz, N., … Bernstein, J. L. (2020). Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. Journal of the National Cancer Institute, 112(12), 1275–1279. https://doi.org/10.1093/jnci/djaa031
Chicago
Reiner, Anne S, Mark E Robson, Lene Mellemkjær, Marc Tischkowitz, Esther M John, Charles F Lynch, Jennifer D Brooks, et al. 2020. “Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.” Journal of the National Cancer Institute 112 (12): 1275–79. doi:10.1093/jnci/djaa031.